Niobium
In clinical developmentAlso known as Nb, columbio, niobio.
Recent clinical, regulatory, research and industry developments relating to this drug.
An artificial spiking afferent nerve based on Mott memristors for neurorobotics.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes3
Journals, researchers & institutions
- Nature communications1
- Fang Y1
- Kiani F1
- Liu M1
- Liu Q1
- Luo Q1
- Midya R1
- Rao M1
- Song W1
- Key Laboratory of Microelectronic Devices and Integrated Technology1
- University of Chinese Academy of Sciences1
- University of Massachusetts1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
- RxNorm (U.S. National Library of Medicine) — drug identity
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials